Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Drugs for Trauma (Emergency, Injury, Surgery) in Preclinical Development in UNITED STATES

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Tellus Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury

              Contact the Supplier

              Lead Product(s): TT-20

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: TT-20

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Xontogeny, LLC

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing May 12, 2021

              Details:

              Tellus’s lead candidate, TT-20, is derived from a class of molecules found in breast milk, which promote oligodendrocyte differentiation in postnatal neural stem cell populations.

              Noveome Biotherapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Noveome Biotherapeutics and Walter Reed Army Institute of Research to Study Noveome’s Lead Product Candidate ST266 in Traumatic Brain Inju...

              Contact the Supplier

              Lead Product(s): ST266

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ST266

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator:<